Bone mineral density in Iranian adolescents and young adults with β-thalassemia major

Pediatric Hematology and Oncology

Volumn 24, Issue 7, 2007, Pages 469-479

  Shamshirsaz, A A ^a,b,d   Bekheirnia, M R ^a,b   Kamgar, M ^a,b   Pakbaz, Z ^c   Tabatabaie, S M ^d   Bouzari, N ^b   Pourzahedgilani, N ^b   Azarkeivan, A ^e   Hashemi, S R ^e   Moosavi, F ^d   Alebouyeh, M ^d   Vosough, P ^e   Kimiagar, M ^d   Moradi, M ^b   Habibzadeh, M R ^b   Nobakhthaghighi, N ^d   Larijani, B ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Charity Foundation for Special Diseases

^c CHILDREN S HOSPITAL OAKLAND   (United States)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone mineral density; Osteopenia; Osteoporosis; Thalassemia

Indexed keywords

ASCORBIC ACID; DEFEROXAMINE MESYLATE; ZINC;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANAMNESIS; ANTHROPOMETRY; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; BONE MASS; CONTROLLED STUDY; DELAYED PUBERTY; ENDOCRINE DISEASE; FEMALE; FEMUR; HUMAN; HYPOGONADISM; IRAN; IRON CHELATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORBIDITY; OSTEOPENIA; OSTEOPOROSIS; PREVALENCE; RISK ASSESSMENT; SCHOOL CHILD; SEX DIFFERENCE; THALASSEMIA MAJOR; TREATMENT DURATION; ZINC BLOOD LEVEL;

ADOLESCENT; BETA-THALASSEMIA; BONE DENSITY; BONE DISEASES, METABOLIC; CHILD; FEMALE; FRACTURES, BONE; HUMANS; IRAN; MALE; OSTEOPOROSIS; PREVALENCE;

EID: 34548400387     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010701533702     Document Type: Article

References (25)

1. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-761.
2. Anapliotou ML, Kastanias IT, Psara P, et al. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol (Oxf). 1995;42:279-287.
3. Molyvda-Athanasopoulou E, Sioundas A, Karatzas N, et al. Bone mineral density of patients with thalassemia major: four-year follow-up. Calcif Tissue Int. 1999;64:481-484.
4. Johanson NA. Musculoskeletal problems in hemoglobinopathy. Orthop Clin North Am. 1990:191-198.
5. Wonke B. Bone disease in beta-thalassaemia major. Br J Haematol. 1998:897-901.
6. Vichinsky EP. The morbidity of bone disease in thalassemia. Ann N Y Acad Sci. 1998;850:344-348.
7. Korovessis P, Papanastasiou D, Tiniakou M, et al. Incidence of scoliosis in beta-thalassemia and follow-up evaluation. Spine. 1996;21:1798-1801.
8. Olivieri NF, Koren G, Harris J, et al. Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol. 1992;14:48-56.
9. Orvieto R, Leichter I, Rachmilewitz EA, et al. Bone density, mineral content, and cortical index in patients with thalassemia major and the correlation to their bone fractures, blood transfusions, and treatment with desferrioxamine. Calcif Tissue Int. 1992;50:397-399.
10. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child. 1976;51:170-179.
11. Garofalo F, Piga A, Lala R, et al. Bone metabolism in thalassemia. Ann N Y Acad Sci. 1998;850:475-478.
12. Jensen CE, Tuck SM, Agnew JE, et al. High incidence of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab. 1998;11(Suppl 3):975-977.
13. Katz K, Horev G, Goshen J, et al. The pattern of bone disease in transfusion-dependent thalassemia major patients. Isr J Med Sci. 1994;30:577-580.
14. De Virgiliis S, Congia M, Frau F, et al. Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr. 1988;113:661-669.
15. Olivieri NF, Basran RK, Talbot AL, et al. Abnormal growth in thalassemia major associated with deferoxamine-induced deferoxamine-induced destruction of spinal cartilage and compromised of sitting height 1995; 482a.
16. Bielinski BK, Darbyshire PJ, Mathers L, et al. Impact of disordered puberty on bone density in beta-thalassaemia major. Br J Haematol. 2003;120:353-358.
17. Voskaridou E, Kyrtsonis MC, Terpos E, et al. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol. 2001;112:36-41.
18. de Boer H, Blok GJ, van Lingen A, et al. Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res. 1994;9:1319-1326.
19. Soliman AT, El Banna N, Abdel Fattah M, et al. Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data. Metabolism. 1998;47:541-548.
20. Dresner Pollack R, Rachmilewitz E, Blumenfeld A, et al. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol. 2000;111:902-907.
21. Chow LH, Frei JV, Hodsman AB, et al. Low serum 25-hydroxyvitamin D in hereditary hemochromatosis: relation to iron status. Gastroenterology. 1985;88:865-869.
22. Rioja L, Girot R, Garabedian M, et al. Bone disease in children with homozygous beta-thalassemia. Bone Miner. 1990;8:69-86.
23. Heaney RP. Nutritional factors in osteoporosis. Annu Rev Nutr. 1993;13:287-316.
24. Lindsay R. Prevention and treatment of osteoporosis. Lancet. 1993;341:801-805.
25. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993:94:646-650.